CORPUS CHRISTI, Texas, May 4, 2006 (PRIMEZONE) -- CSMG Technologies, Inc. (OTCBB:CTUM) announced today that it has received notification that the European Union has granted its patent, "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough." The company previously announced that three U.S. patents and an Australia patent for this technology have been issued.
CSMG President and CEO Donald S. Robbins said, "This is an enormous step for us in this major market and opens the door for licensing opportunities in the European market. We anticipate that we will receive the appropriate licenses for manufacturing, marketing and distribution within the next few months in Eastern Europe, where the technology already has governmental approval and the population base exceeds 300 million people."
CSMG owns the technology and exclusive world rights to a medical device for this procedure through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.
The tissue welding/bonding technology for repair and reconnection of tissue and hollow organs is smokeless, with little heat migration in the tissue. It results in no necrosis and is without the use of foreign matter or conventional wound-closing devices, such as staples, sutures, glues or sealant. The procedures are almost bloodless. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CSMG-patented technology bonds and reconnects incised tissue using a patented low-heat delivery method aimed at restoring the normal functions of the live organs and tissue. The technology leaves little or no scar visible to the naked eye.
About CSMG Technologies' Tissue Welding/Bonding Technology
Surgeons at 10 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 5,000 human surgeries using more than 70 types of open and laparoscopic surgical procedures and demonstrated that the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.
The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at Kiev, Ukraine, headed by Professor B.E. Paton. United States and Australia patents have been issued with other U.S. and foreign patents pending.
About CSMG Technologies
CSMG Technologies maintains offices in Corpus Christi, Texas; Washington D.C.; Atlanta, Ga.; and Kiev, Ukraine. For CSMG's stock quotes, visit http://www.otcbb.com. For more information, visit http://www.ctum.com, e-mail publicrelations@ctum.com, or contact Don Robbins at (361) 887-7546.
Additional information about CSMG can be found at http://www.ctum.com or e-mail publicrelations@ctum.com. An online investor kit containing CSMG press releases, SEC filings, current Level II price quotes, interactive Java, stock charts and other useful information for investors can be found at http://www.hawkassociates.com/csmg and http://www.hawkassociates.com/csmg/kit.htm.
Investors may contact Don Robbins or K. Bruce Jones, CSMG, at (361) 887-7546, publicrelations@ctum.com, or Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 451-1888, info@hawkassociates.com.
Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.